Procrit (epoetin alfa)

DRUG3 trials

Sponsors

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., M.D. Anderson Cancer Center

Conditions

AnemiaGastrointestinal CancerLeukemiaRectal Cancer

Phase 2

Early and Standard Intervention With 120,000 Units of PROCRIT (Epoetin Alfa) Every Three Weeks in Patients Receiving Chemotherapy

CompletedNCT00210600

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Anemia

Start: 2005-05-31End: 2006-08-31Updated: 2011-06-10

Phase 3

A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Weekly Procrit Given to Gastric or Rectal Patients

TerminatedNCT00254436

M.D. Anderson Cancer CenterGastrointestinal Cancer, Rectal Cancer

Start: 2001-10-31End: 2004-06-29Updated: 2018-10-25

Unknown Phase

Procrit Versus No Procrit in Acute Lymphocytic Leukemia, Lymphoblastic Lymphoma, or Burkitt's Undergoing Induction/Consolidation Chemotherapy

CompletedNCT01099202

M.D. Anderson Cancer CenterLeukemia

Start: 2003-03-31End: 2011-05-31Updated: 2012-08-27